Literature DB >> 9018112

Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.

M Rossel1, A Pasini, S Chappuis, O Geneste, L Fournier, I Schuffenecker, M Takahashi, L A van Grunsven, J L Urdiales, B B Rudkin, G M Lenoir, M Billaud.   

Abstract

Germline mutations of the RET proto-oncogene, which codes for a receptor tyrosine kinase, cause multiple endocrine neoplasia type 2A (MEN 2A) and 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC). MEN 2 mutations have been shown to result in RET oncogenic activation. The RET gene encodes several isoforms whose biological properties, when altered by MEN 2 mutations, have not been thoroughly addressed yet. In this study, we have introduced a MEN 2A mutation (Cys634-->Arg) and the unique MEN 2B mutation (Met918-->Thr) in two RET isoforms of 1114 and 1072 amino acids which differ in the carboxy-terminus part. Herein, we report that each RET isoform activated by MEN 2A or MEN 2B mutation was transforming in fibroblasts and induced neuronal differentiation of pheochromocytoma PC12 cells. However, among the different RET-MEN 2 mutants, the long RET isoform activated by the MEN 2B mutation stimulated the most prominent neurite outgrowth in PC12 cells, while the short RET isoform counterpart elicited a very weak differentiation effect in PC12 cells. We further demonstrate that the morphological changes of PC12 cells caused by constitutively activated RET oncoproteins involved the engagement of a Ras-dependent pathway. These findings provide evidence that the biological properties of RET-MEN 2 mutants depend on the interplay between the RET isoforms and the nature of the activating MEN 2 mutation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018112     DOI: 10.1038/sj.onc.1200831

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration.

Authors:  Durga Praveen Meka; Anne Kathrin Müller-Rischart; Prakash Nidadavolu; Behnam Mohammadi; Elisa Motori; Srinivas Kumar Ponna; Helia Aboutalebi; Mahmoud Bassal; Anil Annamneedi; Barbara Finckh; Margit Miesbauer; Natalie Rotermund; Christian Lohr; Jörg Tatzelt; Konstanze F Winklhofer; Edgar R Kramer
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

2.  Protein-tyrosine phosphatase SHP2 contributes to GDNF neurotrophic activity through direct binding to phospho-Tyr687 in the RET receptor tyrosine kinase.

Authors:  Maurice Perrinjaquet; Marçal Vilar; Carlos F Ibáñez
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

Review 3.  Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.

Authors:  Svenja Nölting; Ashley B Grossman
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

4.  C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B.

Authors:  C L Smith-Hicks; K C Sizer; J F Powers; A S Tischler; F Costantini
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

5.  The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease.

Authors:  M C Bordeaux; C Forcet; L Granger; V Corset; C Bidaud; M Billaud; D E Bredesen; P Edery; P Mehlen
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

6.  Critical and distinct roles for key RET tyrosine docking sites in renal development.

Authors:  Sanjay Jain; Mario Encinas; Eugene M Johnson; Jeffrey Milbrandt
Journal:  Genes Dev       Date:  2006-02-01       Impact factor: 11.361

7.  Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.

Authors:  F M Michiels; S Chappuis; B Caillou; A Pasini; M Talbot; R Monier; G M Lenoir; J Feunteun; M Billaud
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

8.  In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation.

Authors:  E Ranza; G Mazzini; A Facoetti; R Nano
Journal:  J Neurooncol       Date:  2009-07-24       Impact factor: 4.130

9.  Ret protein expression in adrenal medullary hyperplasia and pheochromocytoma.

Authors:  James F Powers; Jaime M Brachold; Arthur S Tischler
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 10.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.